Professional Documents
Culture Documents
After recent red flags over the quality of Indian medicines, the government on Wednesday instructed pharma
companies to become compliant with the World Health Organisation’s (WHO) good manufacturing practices
(GMP) that guarantee assured quality for domestic use and export purposes.
The minister said large manufacturers with an annual turnover of over Rs 250 crore had been given six months
to become WHO GMP compliant and those with a turnover of less than Rs 250 crore had been given 12
months for the transition. “Those who don’t comply can lose licences and face hefty financial penalties,”
Mandaviya said.
Of the 10,500 pharmaceutical manufacturing units in India, only 2,000 (19 per cent) have WHO GMP
certification. The Health Ministry on Tuesday notified the pharma industry of the mandate to implement the GMP
under the revised Schedule M of the Drugs and Cosmetics Act, 1940, which was amended in 2018 to ensure
quality control but was never implemented on ground due to laxity of pharma units, which dithered on compliance.
Of these, 33 per cent (71) are in Himachal Pradesh followed by Uttarakhand (46), Madhya Pradesh (23), Gujarat
(16), Punjab (seven), Maharashtra, Tamil Nadu and Delhi five each; Haryana, Karnataka and Telangana four each;
West Bengal three; and Rajasthan, Sikkim, UP, Puducherry, Kerala, Andhra Pradesh, Bihar, Goa and J&K one
each.
Contact +91 98881 11109 OR +91 9131925456 for more details on WHO, EU GMP, US FDA, PICS,
ANVISA plant approvals